The Progression Free Survival of the Dostalema Bar

We will be presenting the interim analysis however most many of the primary endpoints are already matured when we look at those three primary endpoints what we have for the progression we survival. The DMMR population the patients who have deficient MMR there we see unprecedented increase in progression free survival if you look at two years We have a very strong statistically significant improvement long-term benefit in whole group of patients both DMMR and MMRP.